[EN] MODIFIED MRNAS FOR VACCINE DEVELOPMENT<br/>[FR] ARNM MODIFIÉS POUR LE DÉVELOPPEMENT DE VACCINS
申请人:BASECLICK GMBH
公开号:WO2021186028A1
公开(公告)日:2021-09-23
A modified messenger RNA (mRNA) of the present invention encodes within its ORF an antigen such as a viral protein, an immunogenically active part of such viral protein, or an anticancer protein or epitope, and contains at least one of an alkyne- or azide-modification in at least one nucleotide. A preferred viral protein encoded by the inventive mRNA is a Corona virus protein, especially nucleoprotein N of SARS-CoV-2. The modified mRNA or a pharmaceutical com position containing such mRNA is especially useful in the context of a method for vaccination against viral infection and adding an adjuvant like a STING antagonist further enhances the immune response in an individual and accordingly the vaccination efficiency.
An Efficient Method for the Preparation of 1′α-Branched-Chain Sugar Pyrimidine Ribonucleosides from Uridine: The First Conversion of a Natural Nucleoside into 1′-Substituted Ribonucleosides
18 gave the sugar-protected 1'alpha-vinyluridine. With this procedure, 1'alpha-vinyluridine (22) and -cytidine (25), designed to be potential antitumor agents, were successfully synthesized. This study is the first example of functionalization at the anomeric 1'-position of a nucleoside by starting from a natural nucleoside to produce a ribo-type 1'-modified nucleoside.